Acadia Pharma (ACAD) Tops Q3 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Acadia Pharma (ACAD) Tops Q3 EPS by 11c

Acadia Pharma (ACAD) Commences Phase 3 Pivotal Study of Trofinetide in Rett Syndrome

October 31, 2019 5:55 AM EDT

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has initiated the Phase 3 LAVENDER placebo-controlled study to evaluate the efficacy and safety of trofinetide for girls and young women with Rett syndrome. Rett syndrome is a serious and rare neurodevelopmental congenital CNS disorder with symptoms that typically present between six to 18 months of age, and lead to problems with cognitive, sensory, motor, and autonomic function.

There is no approved treatment for Rett syndrome, which is a rare neurological disease that impacts nearly every aspect of a childs life, resulting in loss of speech,... More